Related Experiment Video
Updated: Jul 15, 2026
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models
Yoori Choi1, Hye-Sun Kim, Ki Young Shin
1Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, MRC, Seoul National University, Seoul, South Korea.
Abstract:
Minocycline is a semi-synthetic tetracycline antibiotic that effectively crosses the blood-brain barrier. Minocycline has been reported to have significant neuroprotective effects in models of cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, and Huntington's and Parkinson's diseases. In this study, we demonstrate that minocycline has neuroprotective effects in in vitro and in vivo Alzheimer's disease models. Minocycline was found to attenuate the increases in the phosphorylation of double-stranded RNA-dependent serine/threonine protein kinase, eukaryotic translation initiation factor-2 alpha and caspase 12 activation induced by amyloid beta peptide1-42 treatment in NGF-differentiated PC 12 cells. In addition, increases in the phosphorylation of eukaryotic translation initiation factor-2 alpha were attenuated by administration of minocycline in Tg2576 mice, which harbor mutated human APP695 gene including the Swedish double mutation and amyloid beta peptide(1-42)-infused rats. We found that minocycline administration attenuated deficits in learning and memory in amyloid beta peptide(1-42)-infused rats. Increased phosphorylated state of eukaryotic translation initiation factor-2 alpha is observed in Alzheimer's disease patients' brains and may result in impairment of cognitive functions in Alzheimer's disease patients by decreasing the efficacy of de novo protein synthesis required for synaptic plasticity. On the basis of these results, minocycline may prove to be a good candidate as an effective therapeutic agent for Alzheimer's disease.
Insights
Minocycline demonstrates neuroprotective effects in Alzheimer's disease models by reducing harmful protein phosphorylation and improving memory. This antibiotic shows promise as a potential therapeutic agent for Alzheimer's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Minocycline, a tetracycline antibiotic, penetrates the blood-brain barrier and exhibits neuroprotective properties in various neurological conditions.
- Alzheimer's disease (AD) is characterized by amyloid-beta peptide accumulation and associated cellular stress pathways.
- Dysregulation of protein synthesis, particularly eukaryotic translation initiation factor-2 alpha (eIF2α) phosphorylation, is implicated in cognitive decline in AD.
Purpose of the Study:
- To investigate the neuroprotective effects of minocycline in in vitro and in vivo models of Alzheimer's disease.
- To determine if minocycline can mitigate amyloid-beta-induced cellular damage and cognitive deficits.
Main Methods:
- Utilized NGF-differentiated PC 12 cells treated with amyloid-beta peptide (Aβ1-42) to assess minocycline's effects on protein phosphorylation and caspase activation.
- Administered minocycline to Tg2576 mice and Aβ1-42-infused rats to evaluate its impact on eIF2α phosphorylation and cognitive function.
- Measured learning and memory deficits in animal models.
Main Results:
- Minocycline attenuated Aβ1-42-induced phosphorylation of double-stranded RNA-dependent protein kinase (PKR), eIF2α, and caspase-12 activation in PC 12 cells.
- Minocycline administration reduced eIF2α phosphorylation in both Tg2576 mice and Aβ1-42-infused rats.
- Minocycline treatment improved learning and memory deficits in Aβ1-42-infused rats.
Conclusions:
- Minocycline exhibits significant neuroprotective effects against amyloid-beta toxicity in Alzheimer's disease models.
- The drug's ability to modulate key stress pathways, including eIF2α phosphorylation, suggests a mechanism for its therapeutic potential.
- Minocycline represents a promising candidate for the development of effective Alzheimer's disease therapies.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology